160 related articles for article (PubMed ID: 29278654)
1. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization.
Yasui Y; Tsuchiya K; Kurosaki M; Takeguchi T; Takeguchi Y; Okada M; Wang W; Kubota Y; Goto T; Komiyama Y; Higuchi M; Takaura K; Hayashi T; Takada H; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Enomoto N; Himeno Y; Izumi N
Hepatol Res; 2018 May; 48(6):442-450. PubMed ID: 29278654
[TBL] [Abstract][Full Text] [Related]
2. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9.
Minici R; Ammendola M; Manti F; Siciliano MA; Minici M; Komaei I; Currò G; Laganà D
Front Pharmacol; 2021; 12():634087. PubMed ID: 33897422
[TBL] [Abstract][Full Text] [Related]
4. Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma.
Eso Y; Takai A; Takahashi K; Ueda Y; Taura K; Marusawa H; Seno H
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30909405
[TBL] [Abstract][Full Text] [Related]
5. Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma.
Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Oshita M; Ohkawa K; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2020 Nov; 50(11):1275-1283. PubMed ID: 32812315
[TBL] [Abstract][Full Text] [Related]
6. Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria.
Saito N; Nishiofuku H; Sato T; Maeda S; Minamiguchi K; Taiji R; Matsumoto T; Chanoki Y; Tachiiri T; Kunichika H; Marugami N; Tanaka T
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174075
[TBL] [Abstract][Full Text] [Related]
7. Transarterial- chemoembolization remains an effective therapy for intermediate-stage hepatocellular carcinoma with preserved liver function.
Saito N; Tanaka T; Nishiohuku H; Sato T; Masada T; Matsumoto T; Anai H; Sakaguchi H; Sueyoshi S; Marugami N; Kichikawa K
Hepatol Res; 2020 Oct; 50(10):1176-1185. PubMed ID: 32721060
[TBL] [Abstract][Full Text] [Related]
8. Development of a Model to Predict Liver Decompensation prior to Transarterial Chemoembolization Refractoriness in Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ferreira-Silva J; Costa-Moreira P; Cardoso H; Liberal R; Pereira P; Macedo G
GE Port J Gastroenterol; 2023 Jan; 30(1):29-37. PubMed ID: 36743988
[TBL] [Abstract][Full Text] [Related]
9. The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria.
Takaya H; Namisaki T; Takeda S; Kaji K; Ogawa H; Ishida K; Tsuji Y; Takagi H; Ozutsumi T; Fujinaga Y; Furukawa M; Kitagawa K; Nishimura N; Sawada Y; Shimozato N; Kawaratani H; Moriya K; Akahane T; Mitoro A; Yoshiji H
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768358
[TBL] [Abstract][Full Text] [Related]
10. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
12. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Kim HD; Shim JH; Kim GA; Shin YM; Yu E; Lee SG; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
J Hepatol; 2015 May; 62(5):1076-84. PubMed ID: 25529626
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes.
Shi F; Wu M; Lian SS; Mo ZQ; Gou Q; Xu RD; Li HL; Huang ZM; Wu PH; Chen XM
Radiology; 2019 Dec; 293(3):707-715. PubMed ID: 31638492
[TBL] [Abstract][Full Text] [Related]
14. Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma.
Zhao YN; Zhang YQ; Ye JZ; Liu X; Yang HZ; Cong FY; Xiang BD; Wu FX; Ma L; Li LQ; Ye HH
Exp Ther Med; 2016 Dec; 12(6):3813-3819. PubMed ID: 28105115
[TBL] [Abstract][Full Text] [Related]
15. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
Carling U; Røsok B; Line PD; Dorenberg EJ
Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701
[TBL] [Abstract][Full Text] [Related]
16. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; An C; Sun HL; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Int J Hyperthermia; 2019; 36(1):841-853. PubMed ID: 31452408
[No Abstract] [Full Text] [Related]
17. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
Mazzaferro V; Citterio D; Bhoori S; Bongini M; Miceli R; De Carlis L; Colledan M; Salizzoni M; Romagnoli R; Antonelli B; Vivarelli M; Tisone G; Rossi M; Gruttadauria S; Di Sandro S; De Carlis R; Lucà MG; De Giorgio M; Mirabella S; Belli L; Fagiuoli S; Martini S; Iavarone M; Svegliati Baroni G; Angelico M; Ginanni Corradini S; Volpes R; Mariani L; Regalia E; Flores M; Droz Dit Busset M; Sposito C
Lancet Oncol; 2020 Jul; 21(7):947-956. PubMed ID: 32615109
[TBL] [Abstract][Full Text] [Related]
18. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.
Kim Y; Stahl CC; Makramalla A; Olowokure OO; Ristagno RL; Dhar VK; Schoech MR; Chadalavada S; Latif T; Kharofa J; Bari K; Shah SA
Surgery; 2017 Dec; 162(6):1250-1258. PubMed ID: 29033224
[TBL] [Abstract][Full Text] [Related]
19. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization.
Yoo SH; Jang JW; Kwon JH; Jung SM; Jang B; Choi JY
Clin Mol Hepatol; 2016 Dec; 22(4):458-465. PubMed ID: 28081589
[TBL] [Abstract][Full Text] [Related]
20. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.
Otto G; Herber S; Heise M; Lohse AW; Mönch C; Bittinger F; Hoppe-Lotichius M; Schuchmann M; Victor A; Pitton M
Liver Transpl; 2006 Aug; 12(8):1260-7. PubMed ID: 16826556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
